Cognitive function following SARS-CoV-2 infection in a population-representative Canadian sample

Simple item page
dc.contributor.authorHall, Peter A.en
dc.contributor.authorMeng, Gangen
dc.contributor.authorHudson, Annaen
dc.contributor.authorSakib, Mohammed N.en
dc.contributor.authorHitchman, Sara C.en
dc.contributor.authorMacKillop, Jamesen
dc.contributor.authorBickel, Warren K.en
dc.contributor.authorFong, Geoffrey T.en
dc.coverage.countryCanadaen
dc.date.accessioned2022-09-27T12:59:20Zen
dc.date.available2022-09-27T12:59:20Zen
dc.date.issued2022-05-01en
dc.date.updated2022-09-26T19:27:36Zen
dc.description.abstractBackground: SARS-CoV-2 infection is believed to adversely affect the brain, but the degree of impact on socially relevant cognitive functioning and decision-making is not well-studied, particularly among those less vulnerable to age-related mortality. The current study sought to determine whether infection status and COVID-19 symptom severity are associated with cognitive dysfunction among young and middled-aged adults in the general population, using self-reported lapses in executive control and a standardized decision-making task. Method: The survey sample comprised 1958 adults with a mean age of 37 years (SD ​= ​10.4); 60.8% were female. Participants reported SARS-CoV-2 infection history and, among those reporting a prior infection, COVID-19 symptom severity. Primary outcomes were self-reported symptoms of cognitive dysfunction assessed via an abbreviated form of the Barkley Deficits in Executive Functioning Scale (BDEFS) and performance on a validated delay-discounting task. Results: Young and middle-aged adults with a positive SARS-CoV-2 infection history reported a significantly higher number of cognitive dysfunction symptoms (Madj ​= ​1.89, SE ​= ​0.08, CI: 1.74, 2.04; n ​= ​175) than their non-infected counterparts (Madj ​= ​1.63, SE ​= ​0.08, CI: 1.47,1.80; n ​= ​1599; β ​= ​0.26, p ​= ​.001). Among those infected, there was a dose-response relationship between COVID-19 symptom severity and level of cognitive dysfunction reported, with moderate (β ​= ​0.23, CI: 0.003–0.46) and very/extremely severe (β ​= ​0.69, CI: 0.22–1.16) COVID-19 symptoms being associated with significantly greater cognitive dysfunction. These effects remained reliable and of similar magnitude after controlling for demographics, vaccination status, mitigation behavior frequency, and geographic region, and after removal of those who had been intubated during hospitalization. Very similar—and comparatively larger—effects were found for the delay-discounting task, and when using only PCR confirmed SARS-CoV-2 cases. Conclusions: Positive SARS-CoV-2 infection history and moderate or higher COVID-19 symptom severity are associated with significant symptoms of cognitive dysfunction and amplified delay discounting among young and middle-aged adults with no history of medically induced coma.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier100454 (Article number)en
dc.identifier.doihttps://doi.org/10.1016/j.bbih.2022.100454en
dc.identifier.eissn2666-3546en
dc.identifier.issn2666-3546en
dc.identifier.orcidBickel, Warren [0000-0002-1048-7372]en
dc.identifier.otherPMC8934755en
dc.identifier.otherS2666-3546(22)00044-8 (PII)en
dc.identifier.pmid35340304en
dc.identifier.urihttp://hdl.handle.net/10919/112009en
dc.identifier.volume21en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urihttps://www.ncbi.nlm.nih.gov/pubmed/35340304en
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectBrainen
dc.subjectCOVID-19en
dc.subjectCognitionen
dc.subjectDelay discountingen
dc.subjectExecutive functionen
dc.subjectOFCen
dc.subjectSARS-CoV-2en
dc.subjectLungen
dc.subjectPreventionen
dc.subjectClinical Researchen
dc.subjectNeurosciencesen
dc.subjectBehavioral and Social Scienceen
dc.subjectVaccine Relateden
dc.subjectInfectious Diseasesen
dc.subjectBasic Behavioral and Social Scienceen
dc.subjectInfectionen
dc.subjectMental healthen
dc.titleCognitive function following SARS-CoV-2 infection in a population-representative Canadian sampleen
dc.title.serialBrain, Behavior, and Immunity - Healthen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.otherJournal Articleen
dcterms.dateAccepted2022-03-12en
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/University Research Institutesen
pubs.organisational-group/Virginia Tech/University Research Institutes/Fralin Life Sciencesen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/University Research Institutes/Fralin Life Sciences/Durelle Scotten
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Psychiatry and Behavioral Medicineen
pubs.organisational-group/Virginia Tech/VT Carilion School of Medicine/Psychiatry and Behavioral Medicine/Secondary Appointment-Psychiatry and Behavioral Medicineen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CognitiveFunction.pdf
Size:
641.4 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

All Faculty Deposits
Destination Area: Adaptive Brain and Behavior (ABB)
Scholarly Works, Fralin Biomedical Research Institute at VTC